Our Pipeline

Through the joint efforts of our team and our global partners, we are committed to continuously advancing our compounds.

In addition to clinical-stage programs, we are advancing a diversified portfolio of early-stage projects spanning PHB1/eIF4A small molecules and ADC payloads, CDK8 inhibitors, ERK3 modulators, and antiviral research.